Keywords
How to Cite
Abstract
Benign Prostatic Hyperplasia (BPH) is a common urological condition in older men, characterized by the non-cancerous growth of the prostate gland. It manifests through lower urinary tract symptoms, such as difficulty in urination, increased urinary frequency, and a sensation of incomplete emptying. The diagnosis involves a comprehensive clinical assessment, including imaging tests and measurement of the prostate-specific antigen (PSA). Exploration of the medical literature reveals a intricate narrative about Benign Prostatic Hyperplasia and its surgical approach, prostatectomy. Prostatectomy is a surgical intervention performed to address prostate conditions, most commonly associated with prostate cancer. There are two main approaches: radical prostatectomy, involving the complete removal of the prostate and sometimes the seminal vesicles; and partial prostatectomy, aiming to preserve part of the gland. Indications for prostatectomy include the stage and aggressiveness of cancer, while complications may involve bleeding, infection, and erectile dysfunction. The choice between approaches depends on the individualized assessment of the patient. The relevance of a multidisciplinary team, including urologists, clinicians, surgeons, psychologists, and other healthcare professionals, resonates as a constant theme. This collaboration is crucial not only in interpreting clinical data but also in considering the psychosocial aspects that impact the patient's journey.
References
Ahyai, S. A., Gilling, P., Kaplan, S. A., Kuntz, R. M., Madersbacher, S., Montorsi, F., ... & Te, A. E. (2011). Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. European Urology, 58(3), 384-397.
American Urological Association. (2018). "Guideline for the Management of Benign Prostatic Hyperplasia (BPH)." Retrieved from https://www.auanet.org/guidelines/benign-prostatic-hyperplasia
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., ... & Johansson, J. E. (2014). Radical prostatectomy or watchful waiting in early prostate cancer. New England Journal of Medicine, 370(10), 932-942.
Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H., & Feuer, E. J. (2003). Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute, 95(12), 812-818.
Ficarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., ... & Montorsi, F. (2012). Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. European Urology, 62(3), 405-417.
Litwin, M. S., Tan, H. J., & The Urologic Diseases in America Project. (2015). The diagnosis and treatment of prostate cancer: a review. JAMA, 313(4), 396-405.
McVary, K. T., Roehrborn, C. G., Avins, A. L., Barry, M. J., Bruskewitz, R. C., Donnell, R. F., ... & Raghunathan, T. E. (2011). American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). Retrieved from https://www.auanet.org/guidelines/benign-prostatic-hyperplasia
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., ... & Van den Bergh, R. C. N. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71(4), 618-629.
Platz, E. A., Smit, E., Curhan, G. C., Nyberg, L. M., Giovannucci, E. L. (2005). Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15798410
Roehrborn, C. G. (2011). Benign Prostatic Hyperplasia: An Overview. Retrieved from https://www.uptodate.com/contents/benign-prostatic-hyperplasia-an-overview
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G., ARIA3001 ARIA3002 and ARIA3003 Study Investigators. (2006). Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16536754
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., ... & Van den Bergh, R. C. N. (2017). "EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent." European Urology, 71(4), 618-629.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Mariana Lima de Morais , Isabella Rodrigues Magalhães , Stephanie Meireles Barbosa , Victor Hugo Meireles Barbosa , Isadora Andrade Fonseca Moreira , Maíra Garcia de Almeida , Mauro Soares Marra , Isabela Cher Pimentel Afiune , Matheus Alencar Baía de Oliveira , Arthur Barbosa Mendonça , Luiza Rodrigues Oliveira , Murielle de Almeida Sousa Oliveira , Ana Carolina Teixeira Ferreira Capel , Natália da Silva Barcala , Felippe Narracci